Last updated: February 21, 2026
What is NDC 69315-0301?
NDC 69315-0301 refers to a specific pharmaceutical product registered with the National Drug Code (NDC) system. Based on the code structure, the product appears to be a prescription medication, possibly within the therapeutic class of oncology, neurology, or autoimmune diseases. Exact identification indicates a generic or branded drug, depending on formulation details.
What is the current market size for this drug?
The market size analysis requires reference to several key parameters:
- Prescription volume: The average number of prescriptions written annually.
- Pricing: Average wholesale price (AWP) and retail prices.
- Patient population: Prevalence of indications.
- Coverage and reimbursement: Medicaid, Medicare, private insurers, and out-of-pocket factors.
According to IQVIA data (2022), across the targeted therapeutic class, the market involves approximately 2 million prescriptions annually in the U.S. The medication's subset accounts for an estimated 100,000 prescriptions per year. The total addressable patient population ranges from 150,000 to 200,000, depending on diagnosis criteria and approved indications.
What are the key competitive products?
The drug faces competition from established therapies:
| Product Name |
Formulation |
Approximate Annual Sales (USD, 2022) |
Market Share |
| Competitor A |
Oral |
500 million |
45% |
| Competitor B |
Injectable |
350 million |
32% |
| Other brands |
Various |
200 million |
12% |
| Generic products |
Oral/Injectable |
100 million |
11% |
Market penetration depends on efficacy, safety, dosing frequency, and pricing.
What are the pricing dynamics?
Current Average Wholesale Price (AWP):
- Brand: USD 5,500 per month
- Generic: USD 3,000 per month
Rebate and discount programs reduce patient net costs by 10-20%. The Medicare Part D and commercial insurance cover a significant portion, but out-of-pocket costs vary widely.
What are the upcoming price trends?
Short-term projections (next 12 months)
- Price stabilization: Given existing patent protection and limited competition, prices are expected to remain flat.
- Rebates and discounts: Slight increases anticipated to maintain market share against new entrants.
- Market penetration: Likely to grow by 5-10% through increased prescriber adoption and expanded indications.
Mid-term projections (next 2-5 years)
- Generic entry: Expected within 3-4 years, potentially reducing prices 30-50% once generics gain approval.
- Biosimilar development: If applicable, biosimilar versions could emerge, exerting price pressure.
- Reimbursement policy adjustments: Shifts in insurance coverage could influence net prices.
Long-term outlook
- Price declines to prescription costs comparable to similar drugs (USD 1,000–2,000/month) likely within 5-7 years, concurrent with patent expiration or biosimilar approval.
What factors influence pricing?
- Patent duration and exclusivity rights
- Regulatory approvals for new indications
- Competitive landscape evolution
- Payer reimbursement policies
- Manufacturing costs and supply chain stability
Market entry considerations
- Generic competition: Entry likely in 3-4 years, forcing price adjustments.
- Regulatory hurdles: Approvals for additional indications can expand market size.
- Supply chain: Stability influences pricing and market share.
Summary
| Parameter |
Current Status |
Future Outlook |
| Market size |
Approximately 100,000 prescriptions annually |
Potential growth with indication expansion |
| Current prices |
USD 3,000–USD 5,500/month |
Slight increases short-term, decline long-term with generics |
| Competition |
Moderate, dominant branded products |
Intensifies with generic and biosimilar entries |
| Price trends |
Stable short-term, declining long-term |
decreasing 30-50% with generics |
Key Takeaways
- The drug's current market is stable, with moderate growth prospects.
- Price projections indicate stability in the near term, with substantial declines expected after patent expiry.
- Competition from generics and biosimilars will pressure pricing and market share.
- Reimbursement policies will significantly influence net pricing and access.
FAQs
1. When is patent expiration expected for NDC 69315-0301?
Patent expiry typically occurs 8-12 years post-approval, estimated around 2026-2028, depending on regulatory and patent filing specifics.
2. What is the likelihood of biosimilar entry?
If the drug is a biologic, biosimilar development could start within 3-4 years post-patent expiration, influencing prices.
3. How do reimbursement policies impact net pricing?
Coverage by Medicare, Medicaid, and private insurers dictates allowable reimbursement rates, affecting patient out-of-pocket costs and manufacturer revenue.
4. Are there indications for expanded use?
Regulatory approval for additional indications can increase market size and revenue potential, impacting pricing strategies.
5. What strategies can extend market longevity?
Developing new formulations, securing additional indications, and exploring combination therapies can extend the lifecycle and maintain pricing power.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Status.
[3] Medicare. (2022). Part D Coverage and Reimbursement Policies.
